Tesamorelin is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH). It has been of strong interest in laboratory research for its ability to stimulate growth hormone release and impact metabolic pathways. Preclinical and clinical research studies have highlighted Tesamorelin’s potential roles in body composition, lipid metabolism, and age-related endocrine investigations. While not approved for research outside specific regulated uses, Tesamorelin continues to attract attention as an exciting peptide in metabolic and endocrine-focused research.

Area of Interest

Research into Tesamorelin has focused on:

• Growth Hormone Stimulation: Studied for its capacity to bind GHRH receptors, leading to increased growth hormone secretion in experimental models.
• Metabolic Research: Explored in relation to fat metabolism, insulin sensitivity, and body composition changes in laboratory investigations.
• Lipid Studies: Preclinical and early clinical research has assessed its influence on triglyceride and cholesterol regulation.
• Aging and Endocrinology: Considered in studies looking at hormonal regulation and the physiological changes of aging.

Together, these studies reflect Tesamorelin’s value as a research tool for exploring growth hormone pathways and metabolic health.

Technical Information

• Chemical Name: Tesamorelin acetate
• Synonyms: Egrifta, TH9507
• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: ~5135 g/mol
• Sequence (Amino Acid): His-Trp-Ala-Trp-D-Phe-Lys-Val-Tyr-D-Trp-Leu-Lys-Val-Lys
• CAS Number: 218949-48-5
• Peptide Classification: Synthetic peptide analogue of human growth hormone–releasing hormone (GHRH)

Storage Guidelines

• Lyophilized peptide is stable at room temperature for short periods.
• For long-term storage, keep at −20 °C or below.
• Once reconstituted, store at 2–8 °C. Effective use period may vary depending on the solution used.

Solubility

Tesamorelin is soluble in sterile water or other aqueous buffers depending on formulation and purity.

References

• Fauci, A. S., et al. (2009). “Tesamorelin, a growth hormone–releasing factor analogue, decreases visceral fat in HIV-infected patients with lipodystrophy.” New England Journal of Medicine, 361, 912–922. https://doi.org/10.1056/NEJMoa0903269
• Falutz, J., et al. (2005). “Metabolic effects of tesamorelin, a growth hormone–releasing factor analogue, in HIV patients.” Annals of Internal Medicine, 143(5), 347–356. https://doi.org/10.7326/0003-4819-143-5-200509060-00007
• Allas, S., & Caron, P. (2011). “Tesamorelin: a growth hormone–releasing factor analogue for the treatment of HIV-associated lipodystrophy.” Expert Opinion on Pharmacotherapy, 12(15), 2405–2413. https://doi.org/10.1517/14656566.2011.608699

Certificate of Analysis (COA): Available here